

# Ju Dong Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1357869/publications.pdf>

Version: 2024-02-01

107  
papers

7,243  
citations

101543

36  
h-index

60623

81  
g-index

121  
all docs

121  
docs citations

121  
times ranked

9469  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Diseaseâ€”Associated Hepatocellular Carcinoma in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 670-680.e18.	4.4	22
2	Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLDâ€”related cirrhosis. <i>Hepatology</i> , 2023, 77, 546-557.	7.3	12
3	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 183-193.	4.4	15
4	Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact. <i>Hepatology Communications</i> , 2022, 6, 223-236.	4.3	8
5	Decreasing Trend of Serum Î±-Fetoprotein Level in Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1177-1179.e4.	4.4	13
6	Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1157-e1169.	4.4	12
7	Circulating Tumor Cellâ€”Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissueâ€”Based Messenger RNA Profiling Into a Noninvasive Setting. <i>Liver Transplantation</i> , 2022, 28, 200-214.	2.4	8
8	MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. <i>Journal of Hepatology</i> , 2022, 76, 781-787.	3.7	67
9	A prospective trial to evaluate the performance of the multitarget hepatocellular carcinoma blood test (mt-HBT) for screening at-risk patients: The Altus study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS486-TPS486.	1.6	0
10	Multi-target blood test to improve the performance of hepatocellular carcinoma surveillance programs: A modeling-based virtual trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 405-405.	1.6	1
11	Early detection of primary liver cancer using plasma cellâ€”free DNA fragmentomics: Do all the pieces come together?. <i>Hepatology</i> , 2022, 76, 289-291.	7.3	1
12	HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 128-139.	3.7	139
13	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. <i>Hepatology</i> , 2022, 76, 1649-1659.	7.3	18
14	Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1179-1190.	2.8	7
15	Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017â€”2018. <i>Hepatology Communications</i> , 2022, 6, 2253-2261.	4.3	13
16	Emerging drugs for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 141-149.	2.4	4
17	Hepatic sinusoidal obstruction syndrome due to tacrolimus in a liver-transplantation recipient. <i>Gastroenterology Report</i> , 2021, 9, 485-487.	1.3	4
18	Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 422-436.	7.3	200

#	ARTICLE	IF	CITATIONS
19	Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. Journal of the American College of Surgeons, 2021, 232, 361-371.	0.5	23
20	Sex differences in age at waitlist registration for liver transplantation with nonalcoholic steatohepatitis as primary indication. Clinical Transplantation, 2021, 35, e14163.	1.6	0
21	Nuclear size of circulating tumor cells in advanced prostate cancer to reveal a potential biomarker for clinical outcomes and androgen receptor indifference.. Journal of Clinical Oncology, 2021, 39, 167-167.	1.6	1
22	Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. Advanced Materials Technologies, 2021, 6, 2001056.	5.8	4
23	Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database. Journal of Nuclear Medicine, 2021, 62, 1692-1701.	5.0	9
24	Liver Mass in a Young Male With Ollier Disease. Gastroenterology, 2021, 161, e4-e5.	1.3	0
25	Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. Liver Cancer, 2021, 10, 407-418.	7.7	17
26	Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Liver International, 2021, 41, 1922-1932.	3.9	15
27	A morphological subset of circulating tumor cells in advanced prostate cancer reveals a potential biomarker for clinical outcomes.. Journal of Clinical Oncology, 2021, 39, e17008-e17008.	1.6	0
28	DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. Hepatology Communications, 2021, 5, 1448-1459.	4.3	8
29	BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study. Hpb, 2021, 23, 762-769.	0.3	11
30	High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. Digestive Diseases and Sciences, 2021, , 1.	2.3	8
31	The Role of Extracellular Vesicles in Disease Progression and Detection of Hepatocellular Carcinoma. Cancers, 2021, 13, 3076.	3.7	30
32	Diagnostic Criteria and LI-RADS for Hepatocellular Carcinoma. Clinical Liver Disease, 2021, 17, 409-413.	2.1	18
33	State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States. Hepatology, 2021, 74, 1384-1394.	7.3	26
34	The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. Journal of the National Cancer Institute, 2021, 113, 1531-1541.	6.3	43
35	Abstract 764: Circulating tumor cell-based mRNA scoring system for prognostication of hepatocellular carcinoma - Translating HCC tissue-based mRNA profiling into a non-invasive setting. , 2021, , .		0
36	Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. Hepatology, 2021, 74, 2622-2632.	7.3	31

#	ARTICLE	IF	CITATIONS
37	Estrogen-Driven Growth of Focal Nodular Hyperplasia: Truth or Myth?. ACG Case Reports Journal, 2021, 8, e00531.	0.4	5
38	Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 479.	4.1	15
39	Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. Transplantation Direct, 2021, 7, e635.	1.6	4
40	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2020, 18, 974-983.	4.4	16
41	Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 71, 907-916.	7.3	123
42	REPLY:. Hepatology, 2020, 72, 362-363.	7.3	0
43	Reply. Hepatology, 2020, 72, 364-365.	7.3	0
44	Single-cell mass cytometry on peripheral blood identifies immune cell subsets associated with primary biliary cholangitis. Scientific Reports, 2020, 10, 12584.	3.3	13
45	New advances in the diagnosis and management of hepatocellular carcinoma. BMJ, The, 2020, 371, m3544.	6.0	210
46	Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. Nature Communications, 2020, 11, 4489.	12.8	134
47	Knowledge, Attitudes, and Behaviors of Viral Hepatitis Among Recent African Immigrants in the United States: A Community Based Participatory Research Qualitative Study. Frontiers in Public Health, 2020, 8, 25.	2.7	14
48	Increase in Alcoholic Hepatitis as an Etiology for Liver Transplantation in the United States: A 2004–2018 Analysis. Transplantation Direct, 2020, 6, e612.	1.6	5
49	Circulating tumor cells with small nuclear size: A novel biomarker for survival and clinical outcomes in advanced prostate cancer.. Journal of Clinical Oncology, 2020, 38, e17512-e17512.	1.6	0
50	Association of very small nuclear circulating tumor cell (vsnCTC) with clinical outcomes in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, 168-168.	1.6	0
51	Feasibility of circulating tumor DNA testing in hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2019, 10, 745-750.	1.4	17
52	A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 589-604.	17.8	2,482
53	Circulating Tumor DNA and Hepatocellular Carcinoma. Seminars in Liver Disease, 2019, 39, 452-462.	3.6	27
54	Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA. Theranostics, 2019, 9, 7239-7250.	10.0	59

#	ARTICLE	IF	CITATIONS
55	Screening Indications and Treatments for Cholangiocarcinoma. Current Hepatology Reports, 2019, 18, 408-416.	0.9	2
56	Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986912.	3.2	70
57	Optimal endoscopy timing according to the severity of underlying liver disease in patients with acute variceal bleeding. Digestive and Liver Disease, 2019, 51, 993-998.	0.9	17
58	Early Detection of Hepatocellular Carcinoma: Expanding the Utility of Circulating Tumor Markers. Hepatology, 2019, 69, 1855-1857.	7.3	6
59	GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 531-538.	2.5	135
60	Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. Journal of Viral Hepatitis, 2019, 26, 596-602.	2.0	67
61	The incidence rates and survival of gallbladder cancer in the USA. European Journal of Cancer Prevention, 2019, 28, 1-9.	1.3	36
62	Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clinical and Molecular Hepatology, 2019, 25, 335-343.	8.9	42
63	Does cirrhosis associated with well controlled viral hepatitis confer a risk for extrahepatic cancer?. Hepatology, 2018, 68, 1217-1219.	7.3	2
64	Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors. Annals of Surgery, 2018, 268, 1043-1050.	4.2	18
65	Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. Liver International, 2018, 38, 136-143.	3.9	58
66	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 1684.	4.4	0
67	Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation. Liver Transplantation, 2018, 24, 44-55.	2.4	23
68	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology, 2018, 68, 78-88.	7.3	45
69	More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver International, 2018, 38, 895-902.	3.9	27
70	Green tea consumption: A potential chemopreventive measure for hepatocellular carcinoma?. Hepatology, 2018, 67, 10-12.	7.3	5
71	Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation. Cancer Medicine, 2018, 7, 5870-5878.	2.8	14
72	Management of Combined Hepatocellular Carcinoma-Cholangiocarcinoma. Current Hepatology Reports, 2018, 17, 385-391.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2018, 38, 160-169.	3.6	50
74	Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 103-111.	8.1	177
75	Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1085-1092.	2.5	43
76	Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?. <i>Gut</i> , 2017, 66, 4-5.	12.1	5
77	Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis. <i>Liver Cancer</i> , 2017, 6, 126-136.	7.7	23
78	Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 742-748.	2.2	29
79	Damned if you do, damned if you don't: The evolving story of de novo and recurrent hepatocellular carcinoma amongst those treated with direct-acting antivirals for hepatitis C virus. <i>Liver International</i> , 2017, 37, 809-811.	3.9	2
80	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	6.4	416
81	Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 767-775.e3.	4.4	112
82	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1814.	4.4	1
83	<i>Sleeping Beauty</i> Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors. <i>Cancer Research</i> , 2017, 77, 6576-6588.	0.9	40
84	Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 394.	8.1	2
85	Reply to: “Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence” <i>Journal of Hepatology</i> , 2017, 67, 1357.	3.7	0
86	Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 127-131.e2.	4.4	66
87	Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. <i>Cancer</i> , 2017, 123, 81-89.	4.1	46
88	Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 859-860.	3.7	123
89	Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. <i>Hepatology</i> , 2016, 63, 148-158.	7.3	72
90	Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. <i>American Journal of Gastroenterology</i> , 2016, 111, 1573-1580.	0.4	61

#	ARTICLE	IF	CITATIONS
91	A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 64, 85-91.	7.3	128
92	Weekend Admission for Acute Cholangitis Does Not Adversely Impact Clinical or Endoscopic Outcomes. <i>Digestive Diseases and Sciences</i> , 2016, 61, 53-61.	2.3	11
93	Role of admission serum albumin levels in patients with intracerebral hemorrhage. <i>Acta Neurologica Belgica</i> , 2016, 116, 27-30.	1.1	32
94	Reply. <i>Hepatology</i> , 2015, 61, 1094-1094.	7.3	2
95	Hepatocellular Carcinoma Occurs at an Earlier Age in Africans, Particularly in Association With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2015, 110, 1629-1631.	0.4	68
96	Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. <i>PLoS ONE</i> , 2014, 9, e92273.	2.5	49
97	Metformin does not improve survival in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 15750.	3.3	33
98	Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 714-723.	2.0	125
99	Biliary Tract Cancers in Olmsted County, Minnesota, 1976â€“2008. <i>American Journal of Gastroenterology</i> , 2012, 107, 1256-1262.	0.4	68
100	Surveillance for Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 16-21.	4.4	31
101	Hepatocellular Carcinoma in Olmsted County, Minnesota, 1976-2008. <i>Mayo Clinic Proceedings</i> , 2012, 87, 9-16.	3.0	39
102	Model to estimate survival in ambulatory patients with hepatocellular carcinoma. <i>Hepatology</i> , 2012, 56, 614-621.	7.3	83
103	Factors That Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 617-623.e1.	4.4	116
104	Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 64-70.	4.4	216
105	The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. <i>Seminars in Cancer Biology</i> , 2011, 21, 35-43.	9.6	322
106	Epidemiology and Management of Hepatocellular Carcinoma. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 899-919.	5.1	166
107	Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. <i>Gut and Liver</i> , 2010, 4, 537-542.	2.9	4